India needs investigator-led clinical trials, especially in oncology. Dr BS Ajaikumar, chairman of HealthCare Global Enterprises, said there should be more opportunities to conduct cross-sectional studies.
Dr Reddy's Research facilities Ltd. (DRL) beat expert assumptions to report a net profit of ₹1,378.9 crore in the second from last quarter finished December (Q3FY24), a 11% year-on-year rise, helped by piece of the pie gains. During that time, the...
Sonablate is pleased to present its most recent innovation At the Rajiv Gandhi Cancer Institute and Research Centre in Delhi. Sonablate HIFU (Extreme focus Centered Ultrasound) innovation. Patients with prostate conditions can now receive precise...
After stabilization with intravenous immunoglobulin therapy, Takeda announced that the European Commission granted approval to Hyqvia (Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase) as maintenance therapy for patients...
As February 1, the day Finance Minister Nirmala Sitharaman presents Financial plan 2024, moves close, drug and medical care areas drill down their assumptions. Advancement in medical care and pharma, changes in health care coverage, lifting...
Formosa Pharmaceuticals (Formosa) of Taiwan has announced that it has signed a licensing agreement with Cristália Produtos Qumicos Farmacêuticos Ltda (Cristália) for exclusive Brazilian rights to the commercialization of APP13007 (clobetasol...
Vanda Drugs Inc. (Vanda), a main worldwide biopharmaceutical organization, reported that the US Patent and Brand name Office has given a notification of recompense for its Ponvory (ponesimod) patent application, number 17/962,968, covering...
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) have approved the diabetes and weight management drug Mounjaro (tripeptide), a four-part version (with one month of treatment) of the Mounjaro KwikPen.
Abbott said he had received approval from the United States. The Food and Drug Administration (FDA) will launch the Liberta RC DBS system, the world's most minor deep brain stimulation (DBS)
The US Food and Drug Administration (FDA) have approved Dupixent (dupilumab) for the treatment of pediatric patients 1 to 11 years of age and weighing 15 kg or more with eosinophilic esophagitis (EoE).
, CDSCO.jpg)
